105579-43-9

Basic information

• Product Name: (8beta,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline
• CAS NO: 105579-43-9
• Molecular Formula: C₁₉H₂₂N₄
• Molecular Weight: 306.4048
• Mol File: 105579-43-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 560.8°C at 760 mmHg
• Flash Point: 293°C
• Density: 1.35g/cm³
• Vapor Pressure: 1.31E-12mmHg at 25°C
• Refractive Index: 1.74
• CAS DataBase Reference: (8beta,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline(CAS DataBase Reference)
• NIST Chemistry Reference: (8beta,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline(105579-43-9)
• EPA Substance Registry System: (8beta,10xi)-8-(1H-imidazol-1-ylmethyl)-6-methylergoline(105579-43-9)

Safety Data

• Hazardous Substances Data: 105579-43-9(Hazardous Substances Data)

Upstream product

• 288-32-4 1H-imidazole 
• 58752-31-1 6-methyl-8β-tosyloxymethyl-ergoline 
• 96737-35-8 6-methyl-8α-(toluene-4-sulfonyloxymethyl)-ergoline 
• 3006-19-7 9,10-dihydrolysergic acid methyl ester 
• 5878-43-3 9,10-dihydrolysergic acid 
• 18051-16-6 9,10-dihydrolysergol 

Relevant articles and documents

Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity

A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were tested in conscious spontaneously hypertensive rats and in rats with unilateral 6- hydroxydopamine-induced lesions of the substantia nigra. (5R,8R,10R)-6- Alkyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18- fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4- Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active than bromocriptine mesylate and pergolide mesylate, respectively. Several compounds exhibited potent antihypertensive activity. Structure- activity relationships for antihypertensive and dopaminergic activities are discussed.

Ergoline derivatives and acid addition salts thereof

Novel ergoline derivatives and acid addition salts thereof are disclosed. These ergoline derivatives possess excellent anti-hypertensive activity, vasodilating activity, anti-ulcer activity, gastric secretion inhibitory activity, brain metabolism improving activity, anti-depressive activity and dopamine-like activity, and, therefore, are useful for prevention and treatment of various diseases such as hypertension, a wide variety of vein disorders, peptic ulcer, brain absormality, depression, Parkinson's disease, high prolactin blood disease, etc.